Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Centanafadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 10/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 10/20 | 1.00 |
| ▸ | SLC6A3 known ✓ | Q01959 | 10/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.69 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Centanafadine SCHEMBL29705758 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL17911611 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL13698169 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL4177088 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL13698302 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL16214791 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL4194713 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL13698168 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL16213933 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 | |
| Centanafadine SCHEMBL30033872 | 1.00 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138950-A1 | CRYSTALLINE COMPOUNDS | OTSUKA AMERICA PHARMACEUTICAL INC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4577195-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CENTANAFADINE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2025-07-02 | — | — | EP | claimed |
| US-12042481-B2 | Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2024-07-23 | — | — | US | claimed |
| WO-2024043260-A1 | PHARMACEUTICAL COMPOSITION COMPRISING CENTANAFADINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-02-29 | — | — | WO | claimed |
| US-20220409579-A1 | METHODS OF TREATING BINGE EATING DISORDER | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2022-12-29 | — | — | US | claimed |
| US-20220347157-A1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING (1R, 5S)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2022-11-03 | — | — | US | claimed |
| EP-3597189-B1 | CRYSTALLINE COMPOUNDS | OTSUKA AMERICA PHARMACEUTICAL INC (US) | 2022-06-01 | — | — | EP | claimed |
| US-20210047268-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMISTTERS | ETHISMOS RESEARCH, INC. | 2021-02-18 | — | — | US | claimed |
| EP-2719384-B1 | Novel 1-naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL INC (US) | 2018-08-08 | — | — | EP | claimed |
| US-20180008575-A1 | METHODS OF TREATING BINGE EATING DISORDER | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2018-01-11 | — | — | US | claimed |
| WO-2015089111-A1 | NOVEL METHODS | NEUROVANCE, INC. (US) | 2015-06-18 | — | — | WO | claimed |
| US-20150148399-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2015-05-28 | — | — | US | claimed |
| US-8877798-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2014-11-04 | — | — | US | claimed |
| US-20140228421-A1 | Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters | ETHISMOS RESEARCH, INC. | 2014-08-14 | — | — | US | claimed |
| US-20140206740-A1 | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters | NEUROVANCE, INC. (US) | 2014-07-24 | — | — | US | claimed |
| EP-2719384-A1 | Novel 1 -naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neurophychiatric disorders | Euthymic Bioscience, Inc. (US) | 2014-04-16 | — | — | EP | claimed |
| US-8461196-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | DOV PHARMACEUTICAL | 2013-06-11 | — | — | US | claimed |
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2012-11-29 | — | — | US | claimed |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | claimed |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047268-A1 | METHODS FOR INHIBITING NATIVE AND PROMISCUOUS UPTAKE OF MONOAMINE NEUROTRANSMISTTERS | SLC18A2, SLC6A2, SLC6A3 | SLC6A2 2/4885SLC6A4 5/4885SLC6A3 3/4885 |
| US-20140228421-A1 | Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters | SLC18A2, SLC6A2, SLC18A3 | SLC6A2 2/4885SLC6A4 5/4885SLC6A3 4/4885 |
| US-20140206740-A1 | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters | HTR5A, CHRNA5, HTR1B | SLC6A2 9/4885SLC6A4 66/4885SLC6A3 25/4885 |
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | SLC6A2 276/4885SLC6A4 221/4885SLC6A3 92/4885 |
| US-20220347157-A1 | SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING (1R, 5S)-1-(NAPHTHALEN-2-YL)-3-AZABICYCLO[3.1.0]HEXANE | ABCB11, NAP1L1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | SLC6A2 212/4885SLC6A4 487/4885SLC6A3 587/4885 |
| US-20180008575-A1 | METHODS OF TREATING BINGE EATING DISORDER | ADH1C, EBP, DBH | SLC6A2 107/4885SLC6A4 184/4885SLC6A3 33/4885 |
| US-12042481-B2 | Use of (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane in the treatment of conditions affected by monoamine neurotransmitters | HTR5A, CHRNA5, HTR1A | SLC6A2 23/4885SLC6A4 75/4885SLC6A3 31/4885 |
| US-20260138950-A1 | CRYSTALLINE COMPOUNDS | HTR5A, TPH1, SLC6A2 | SLC6A2 3/4885SLC6A4 6/4885SLC6A3 7/4885 |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1B, HTR2C | SLC6A2 276/4885SLC6A4 221/4885SLC6A3 92/4885 |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | SLC6A2 276/4885SLC6A4 221/4885SLC6A3 92/4885 |
| US-20220409579-A1 | METHODS OF TREATING BINGE EATING DISORDER | ADH1C, EBP, DBH | SLC6A2 107/4885SLC6A4 184/4885SLC6A3 33/4885 |
| US-20150148399-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | SLC6A2 276/4885SLC6A4 221/4885SLC6A3 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.